## 1 Understanding the impact of disease and vaccine mechanisms on the importance 2 of optimal vaccine allocation\*

Isobel R. Abell<sup>1, 2</sup>, James M. McCaw<sup>1, 3, 4</sup>, and Christopher M. Baker<sup>1, 2, 5</sup>

<sup>1</sup>School of Mathematics and Statistics, The University of Melbourne, Melbourne, Australia
<sup>2</sup>Melbourne Centre for Data Science, The University of Melbourne, Melbourne, Australia
<sup>3</sup>Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia
<sup>4</sup>Peter Doherty Institute for Infection and Immunity, The Royal Melbourne Hospital and The University of Melbourne, Australia
<sup>5</sup>Centre of Excellence for Biosecurity Risk Analysis, The University of Melbourne, Melbourne,

Australia

Abstract. Vaccination is an important epidemic intervention strategy. Resource limitations and an imperative 13 14 for efficient use of public resources drives a need for optimal allocation of vaccines within a population. For a disease causing severe illness in particular members of a population, an effective strategy 15to reduce illness might be to vaccinate those vulnerable with a vaccine that reduces the chance of 17 catching a disease. However, it is not clear that this is the best strategy, and it is generally unclear how the difference between various vaccine strategies changes depending on population characteris-18 19tics, vaccine mechanisms and allocation objective. In this paper we develop a mathematical model to 20 consider strategies for vaccine allocation, prior to the establishment of community transmission. By extending the SEIR model to incorporate a range of vaccine mechanisms and disease characteristics, 22 we study the impact of vaccination on a population comprised of individuals at high and low risk 23of infection. We then compare the outcomes of optimal and suboptimal vaccination strategies for a range of public health objectives using numerical optimisation. Our comparison shows that the 24 difference between vaccinating optimally and suboptimally is dependent on vaccine mechanism, dis-26 eases characteristics, and objective considered. Even when sufficient vaccine resources are available, 27allocation strategy remains important as allocating suboptimally could result in a worse outcome than allocating limited vaccine resources optimally. This work highlights the importance of designing 28 29effective vaccine allocation strategies, as allocation of resources can be just as crucial to the success 30 of the overall strategy as total resources available.

**1. Introduction.** Pre-epidemic vaccination is an important intervention for managing disease, and when supply is limited vaccines should be used strategically as part of pandemic preparedness. The difference in the outcomes of various allocation strategies will depend on the characteristics of the pathogen and on vaccine mechanisms. Understanding how these characteristics affect both the optimal allocation strategy and the difference in outcomes between strategies is vital when planning vaccine allocation for novel pathogens or pathogen strains.

\*Submitted to the editors DATE.

3

11

12

1

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

When new viruses emerge, we aim to design effective vaccination strategies based on knowledge

2

#### 38

of previous pandemics and emerging information [1, 2]. For example, when vaccinating against 40influenza, there are benefits to targeting vaccination towards those most vulnerable to disease, 41 and targeting vaccination towards those most likely to spread disease [3, 4]. However, these 42benefits are highly dependent on disease parameters as well as relative efficacy of the vaccine 43 between population groups [5, 6]. When vaccines are available or potential vaccines are in 44 development for novel pathogens, modelling has been used to develop optimal vaccination 45strategies [7, 8]. However, any strategy developed must be regularly reevaluated as new virus 46 variants emerge. For example, the emergence of new variants for COVID-19 in 2021, notably 47 the Delta and Omicron variants, have necessitated the reevaluation of current intervention 48 strategies. As more information became available about the characteristics of the Delta and 49 Omicron variants, many countries adapted their vaccination strategies to prioritise booster 50doses [9, 10], partly due to decreased vaccine effectiveness. 51Mathematical modelling provides the tools to quantify how vaccine mechanisms and disease 52 characteristics may affect the optimal impact of vaccine allocation. For simple epidemiological 53 models such as the SIR or SEIR model, we can calculate the threshold vaccination needed to 54ensure  $R_0 < 1$  which ensures sustained transmission is not possible. While we can derive the 55 56 threshold of vaccination to ensure  $R_0 < 1$  for more complex models, the relationship between various objectives such as total infections or deaths and  $R_0$  is no longer as simple as before. 57As such, calculating the number of vaccines needed to optimise a specific objective requires 58 careful thought and potentially numerical methods. Realistically, we may instead compare a range of vaccination strategies to determine which results in the best outcome for a given 60 objective, deeming this the optimal of the strategies considered [3, 7, 8, 11]. In general, the 61 specific public health objective considered impacts results, so we need to consider which model 62 outputs, such as total infections, total symptomatic infections and total deaths, are most ap-63 propriate to minimise when optimising a vaccine allocation strategy [12]. 64

65

Two important areas related to pre-epidemic vaccination are predicting optimal vaccine allocation to prepare for potential pandemics, and designing optimal vaccine allocation strategies based on limited information from novel pandemics. To predict the optimal allocation strategy for potential pandemics, we want to know who to vaccinate and when to vaccinate. Vaccines are generally most effective when allocated early in the outbreak and rapidly, focusing primarily on vulnerable people and highly transmissible groups [3, 4, 6, 13, 14]. When a pandemic begins, we can apply the findings from this literature to predict effective strategies

3

based on what information is available. For both influenza and COVID-19, optimal vac-73 cine strategies depend on how transmissibility, severity and vaccine effectiveness vary by age 74 [4, 11, 7, 15, 16, 8]. While these analyses focus on predicting the optimal vaccine allocation strategy, they do not present a generalised understanding of difference between optimal and suboptimal strategies. Are there certain situations where vaccine coverage should be priori-77 tised, irrespective of who gets vaccinated? Or are there situations where we should ensure 78 every available vaccine is allocated optimally? 79

80

In this paper we determine optimal vaccination strategies for a range of vaccine mechanisms 81 82 and strategic objectives, and compare the outcomes of optimal and suboptimal strategies. We take a deterministic modelling approach and consider the effects of four separate vaccine 83 mechanisms on a population comprised of people at high and low risk of infection. We deter-84 mine the optimal allocation strategies for this population for a variety of allocation objectives. 85 Through comparing the outcomes of optimal and suboptimal allocation strategies, we investi-86 gate how disease characteristics and vaccine characteristics (such as vaccine effectiveness and 87 coverage) impact the differences in outcomes for various strategies. This analysis explores how 88 the benefits of prioritising better vaccine resources over targeted allocation change depending 89 on the scenario considered. 90

2. Method. We define a modified SEIR model with two age classes, symptomatic and 91 asymptomatic infection, and death due to disease. We consider vaccine mechanisms that 92 prevent transmission, or symptomatic or severe disease, and consider scenarios where people 93 are vaccinated before an epidemic starts. Through numerical simulation of our model, we aim 94 to minimise either total infections, symptomatic infections or deaths and explore how disease 95 and vaccine characteristics affect the outcome of various vaccine allocation strategies. 96

**2.1.** Transmission model. To model the effects of pre-epidemic vaccination, we extend the 97 SEIR model for two population groups to include vaccination, asymptomatic and symptomatic 98 disease progression, and death due to disease. We define our model from the following disease 99 progression: 100

- 102
- Each population group is initially split into *unvaccinated* and *vaccinated* susceptibles, 101 • If infected, a susceptible person becomes *exposed*, where they are infected but not yet
- infectious, 103
- 104 • An exposed person will become *infectious*, developing either symptomatic or asymptomatic disease, 105
- 106
- A person with symptomatic disease can either *recover* from disease, or *die* due to


4

- infection,
- A person with asymptomatic disease will *recover* from disease.

109 We define an ODE model from these assumptions, as shown in the compartmental diagram

- 110 in Figure 1.
- 111

107



**Figure 1:** Compartmental diagram for our extended SEIR model. Initially people are either susceptible  $(U_i)$  or vaccinated  $(V_i)$  where  $i \in \{1, 2\}$  denotes population group. Both classes are able to become exposed  $(E_{ji})$  and then infected  $(I_{jki})$  where  $j \in \{U, V\}$  denotes whether they were initially unvaccinated or vaccinated and  $k \in \{S, A\}$  denotes if they experience symptomatic or asymptomatic disease. From here, symptomatic people or asymptomatic can recover from disease  $(R_{jki})$  or symptomatic people can also die due to disease  $(D_{ji})$ . For each group,  $\omega_i$  denotes the probability of developing symptomatic infection and  $\sigma_i$  denotes the probability of dying due to disease. We define vaccine effectiveness for each mechanism as  $1 - \alpha_m$  for  $m \in \{1, 2, 3, 4\}$ . We consider mechanisms: 1) reducing susceptibility, 2) reducing probability of developing symptomatic infection, 3) reducing probability of dying due to disease, and 4) reducing infectivity. In the force of infection  $\lambda_i$ ,  $1 - \delta_A$  denotes the reduction in infectivity due to asymptomatic infection and  $LP_i$  denotes the number of people alive in Group j.

- 112 In our model, we define compartments  $X_{jki}$ , where
- $X \in \{U, V, E, I, R, D\}$ : denotes compartment types; unvaccinated, vaccinated, ex-
- 114 posed, infected, recovered and dead,

5

115	• $j \in \{U, V\}$ : denotes unvaccinated or vaccinated disease progression,
116	• $k \in \{S, A\}$ : denotes symptomatic or asymptomatic infection, and
117	• $i \in \{1, 2\}$ : denotes population group (1: high risk of infection, 2: low risk of infection).
118	

- 119 We incorporate the varying risk of infection between population groups by assuming people
- 120 in Group 1 (high risk) are twice as susceptible to infection than people in Group 2 (low risk).
- 121 From this assumption, we define a contact matrix C:

122 (2.1) 
$$C = \begin{array}{c} I_1 & I_2 \\ S_2 & \begin{bmatrix} 2 & 2 \\ 1 & 1 \end{bmatrix}, \\ C = \begin{array}{c} S_1 \\ S_2 \end{bmatrix} \begin{bmatrix} 2 & 2 \\ 1 & 1 \end{bmatrix},$$

123 where Group 1 is high risk and Group 2 is low risk, S denotes the susceptible groups (S<sub>i</sub> and

124  $V_i$ ) and I denotes the infected groups  $(I_{SSi}, I_{SAi}, I_{VSi} \text{ and } I_{VAi})$ .

125

To investigate the effects of a range of vaccine mechanisms, we consider four vaccine mechanisms [16]:

- 128 1. Reduction in susceptibility,
- 129 2. Reduction in probability of developing symptomatic infection,

130 3. Reduction in probability of dying due to disease, and

131 4. Reduction in infectivity.

132

We define the effectiveness of each vaccine as  $1 - \alpha_{m \in \{1,2,3,4\}} \in [0,1]$ , corresponds to the vaccine number as defined above. An 100% effective vaccine  $(1 - \alpha_m = 1)$  corresponds to a perfect vaccine, for example if  $\alpha_1 = 0$ , vaccinated individuals are unable to be infected. Conversely, a 0% effective vaccine  $(1 - \alpha_m = 0)$  corresponds to the vaccine having no effect. As we only consider pre-epidemic vaccination, vaccine allocation appears in the initial conditions for the vaccinated compartments for Groups 1 (high risk) and 2 (low risk).

In this model, we assume frequency dependent transmission i.e. the transmission rate depends on the proportion of infecteds in the population as the contact rate is independent of population size. This is preferred for modelling human populations over density dependent transmission as we determine our contacts by social constraints, which do not necessarily scale with population size [5]. We further assume progress on a fast enough timescale that we can ignore births and natural deaths and that the population is closed. Therefore, total

6

population for each group  $P_{i \in \{1,2\}}$  is constant, but this population also includes people who 146have died due to disease. To implement frequency dependent transmission, we define a new 147 population size  $LP_{i \in \{1,2\}}(t)$  which denotes the size of the *living* population for each group. 148 This living population will change over time as people die due to disease. As people die and no 149 longer have contact with living people (we assume), for the same number of infected people, 150the proportion of infected contacts will increase. 151152From the assumptions stated above, we derive the ODEs to describe our model. In addition 153to the standard SEIR model parameters and the vaccine effectiveness parameters  $\alpha_m, \omega_i$  de-154notes the proportion of exposed individuals that become symptomatically infected,  $\sigma_i$  denotes 155the proportion of symptomatic individuals who die due to disease, and  $1 - \delta_A$  denotes the 156reduction in infectivity for asymptomatic infecteds, all for a population group i. Furthermore, 157 $[C_{ij}]$  denotes the elements of the contact matrix as defined in Eq. (2.1),  $P_j$  denotes the size of 158Group j at the beginning of the epidemic, and  $LP_j(t)$  denotes the size of the living population 159of Group *i*. Our model is hence by the following equations for each population group: 160

161 162

Unvaccinated:

163 (2.2) 
$$\frac{dU_i}{dt} = -\lambda_i(t)U_i(t)$$

164 (2.3) 
$$\frac{dE_{Ui}}{dt} = \lambda_i(t)U_i(t) - \theta E_{Ui}(t)$$

165 (2.4) 
$$\frac{dI_{USi}}{dt} = \omega_i \theta E_{Ui}(t) - \gamma I_{USi}(t)$$

166 (2.5) 
$$\frac{dI_{UAi}}{dt} = (1 - \omega_i)\theta E_{Ui}(t) - \gamma I_{UAi}(t)$$

167 (2.6) 
$$\frac{dR_{USi}}{dt} = (1 - \sigma_i)\gamma I_{USi}(t)$$

168 (2.7) 
$$\frac{dD_{Ui}}{dt} = \sigma_i \gamma I_{USi}(t)$$

$$\begin{array}{c} 169\\170 \end{array} \quad (2.8) \qquad \qquad \frac{d\mathcal{R}_{UAi}}{dt} = \gamma I_{UAi}(t) \end{array}$$

171

Vaccinated:

7

(2.9) 
$$\frac{dV_i}{dt} = -\alpha_1 \lambda_i(t) V_i(t)$$

173 (2.10) 
$$\frac{dE_{Vi}}{dt} = \alpha_1 \lambda_i(t) V_i(t) - \theta E_{Vi}(t)$$

174 (2.11) 
$$\frac{dI_{VSi}}{dt} = \alpha_2 \omega_i \theta E_{Vi}(t) - \gamma I_{VSi}(t)$$

175 (2.12) 
$$\frac{dI_{VAi}}{dt} = (1 - \alpha_2 \omega_i)\theta E_{Vi}(t) - \gamma I_{VAi}(t)$$

176 (2.13) 
$$\frac{dR_{VSi}}{dt} = (1 - \alpha_3 \sigma_i)\gamma I_{VSi}(t)$$

177 (2.14) 
$$\frac{dD_{Vi}}{dt} = \alpha_3 \sigma_i \gamma I_{VSi}(t)$$

178 (2.15) 
$$\frac{dR_{VAi}}{dt} = \gamma I_{VAi}(t).$$

180

## Force of infection

181 (2.16) 
$$\lambda_{i}(t) = \sum_{j=1}^{2} \beta C_{ij} \frac{I_{USj}(t)}{LP_{j}(t)} + \delta_{A} \beta C_{ij} \frac{I_{UAj}(t)}{LP_{j}(t)} + \alpha_{4} \left[ \beta C_{ij} \frac{I_{VSj}(t)}{LP_{j}(t)} + \delta_{A} \beta C_{ij} \frac{I_{VAj}(t)}{LP_{j}(t)} \right]$$
182 (2.17) 
$$\Rightarrow \lambda_{i}(t) = \sum_{j=1}^{2} \frac{\beta C_{ij}}{LP_{j}(t)} \left( I_{USj}(t) + \delta_{A} I_{UAj}(t) + \alpha_{4} \left[ I_{VSj}(t) + \delta_{A} I_{VAj}(t) \right] \right)$$
183

184 Adding Eqs. (2.2)-(2.15) we find:

185
$$\sum_{\substack{i \in \{1,2\}\\j \in \{U,V\}\\k \in \{S,A\}}} \frac{dU_i}{dt} + \frac{dV_i}{dt} + \frac{dE_{ji}}{dt} + \frac{dI_{jki}}{dt} + \frac{dR_{jki}}{dt} + \frac{dD_{ji}}{dt} = 0$$
186
$$\Rightarrow \sum_{\substack{i \in \{1,2\}\\j \in \{U,V\}\\j \in \{U,V\}\\k \in \{S,A\}}} U_i(t) + V_i(t) + E_{ji}(t) + I_{jki}(t) + R_{jki}(t) + D_{ji}(t) = \sum_{i \in \{1,2\}} P_i$$
187

where we define  $P_1$  and  $P_2$  as the population sizes of Groups 1 and 2 at the beginning of the epidemic. For our analysis we assume  $P_1 = P_2$ . As the epidemic progresses and people die due to disease, we define the living population size  $LP_{i \in \{1,2\}}(t)$  as:

191 
$$LP_i(t) = P_i - D_{Ui}(t) - D_{Vi}(t).$$

192 Given both Groups 1 and 2 start with  $I_0$  infections each, and  $v_1$  and  $v_2$  vaccinations respec-

8

193 tively, Eqns (2.2)–(2.15) have the following initial conditions:

194 
$$U_i(0) = P_i - v_i - I_0$$

$$V_i(0) = v_i$$

196 
$$E_{ji}(0) = 0$$

197 
$$I_{Uki}(0) = \frac{1}{2}I_0$$

$$I_{Vki}(0) = 0$$

$$R_{jki}(0) = 0$$

$$200 D_{ji}(0) = 0,$$

for  $i \in \{1, 2\}$ ,  $j \in \{U, V\}$  and  $k \in \{S, A\}$ . That is, we assume there are initially  $2I_0$  infected people with  $I_0$  infected people in each population group. For each population group all initially infected people are unvaccinated with half symptomatic and the other half asymptomatic, which is why  $I_{Uki}(0)$  is equal to  $\frac{1}{2}I_0$  for  $k \in \{S, A\}$ . In our analysis we assume  $I_0 = 50$ . Complete modelling details are given in the supplementary material.

207 **2.2. Optimising Vaccine Allocation.** To find the optimal vaccine allocation strategy, we 208 compute the number of vaccines allocated to each population group to minimise a given 209 objective function. Given we consider a finite number of vaccines  $(v_{max})$  and two population 210 groups, the problem reduces to finding the number of vaccines to allocate to Group 1  $(v_{opt})$ 211 to minimise the objective function:

212 (2.18) 
$$v_{opt} = \min_{v \in \{1, \dots, v_{max}\}} \{ \text{objective function}(y(v)) \},$$

where y is the output from the model Eqs. (2.2)–(2.15) with initial conditions  $V_1(0) = v$  and  $V_2(0) = v_{max} - v$ .

215

216 The three objective functions that we consider are:

217 1. Total infections:

218

$$\sum_{\substack{i \in \{1,2\}\\j \in \{U,V\}\\k \in \{S,A\}}} R_{jki}(\infty) + D_{ji}(\infty)$$

219 2. Total symptomatic infections:

220

$$\sum_{\substack{i \in \{1,2\}\\j \in \{U,V\}}} R_{jSi}(\infty) + D_{ji}(\infty)$$

3. Total deaths:

221 222

 $\sum_{\substack{i \in \{1,2\}\\j \in \{U,V\}}} D_{ji}(\infty)$ 

where  $X(\infty) := \lim_{t \to \infty} X(t)$  denotes the size of compartment X at the end of the epidemic.

We aim to compare optimal and suboptimal strategies for discrete and continuous variables. 225For discrete variables, we will compare the outcomes of a variety of strategies generated by 226allocating all vaccines in varying proportions to each group. For continuous variables, we will 227 compare the outcome of the optimal strategy with the outcomes of vaccinating each group 228 229 equally (an uninformed strategy) and vaccinating poorly. We calculate the poor strategy by comparing the outcome of a variety of strategies and selecting the worst. For example, if the 230optimal strategy prioritises vaccinating for Group 1 (high risk) and a poor strategy was found 231 to prioritise vaccinating for Group 2 (low risk), our three comparison strategies are: 232

1. Optimal strategy: prioritise vaccinating Group 1,

234 2. Uninformed strategy: vaccinate Groups 1 and 2 equally,

3. Poor strategy: prioritise vaccinating Group 2.

236

The results presented here were generated using MATLAB 9.10. The model was simulated using ode45 and as the optimisation problem reduces to one dimension, the optimal strategy was computed using fmincon.

**3. Results.** We present our results through the following analysis:

- 1. How do disease characteristics lead to variation in the differences in outcomes betweenoptimal and suboptimal vaccination strategies?
- 243
  243 2. How does the difference in outcome between optimal and suboptimal strategies depend
  244 on vaccine effectiveness and coverage?
- When examining our results, it is useful to think about the direct and indirect effects of various parameters or vaccine mechanisms. We use "direct effects" to mean mechanisms that impact only vaccinated individuals, for example if the vaccine reduces the probability of hos-
- 248 pitalisation. Conversely, we use "indirect effects" to refer to mechanisms that both vaccinated

#### 10

and unvaccinated individuals, for example if a vaccine results in reduced transmission.

In the following sections we provide a subset of model results, which explore interest aspects of our model. However, we also provide a complete set of model results in the supplementary material.

**3.1.** Varying disease characteristics. Here we present results that consider how the dif-253ference between optimal and suboptimal strategies is dependent on disease characteristics for 254various vaccine mechanisms and allocation objectives. We consider vaccination strategies for 255a 75% effective vaccine with 50% vaccine coverage. These values have been chosen arbitrar-256ily to demonstrate the effects of varying disease characteristics. As we assume Group 1 and 257Group 2 are the same size, 50% vaccine coverage provides interesting results as it gives us the 258potential to vaccinate the entirety of one population group. Furthermore, we are interested 259in relatively effective vaccines, but still want to capture their imperfection and so we choose 260an effectiveness of 75%. Unless otherwise stated, we assume a total population of size of 261N = 10000, with 5000 people in each group  $(P_1 = P_2 = 5000)$ . 262


263

The plots in Figure 2 show the effects of varying a parameter that affects transmission  $(R_0)$ and another that affects infection characteristics  $(\sigma)$  on the difference between optimal and suboptimal allocation strategies.


267

We consider the effect of varying  $R_0$  on the difference in outcomes between strategies as shown 268 in Figure 2a. Mathematically, there are two points of interest in this figure, the initial con-269 vexity of all the strategies and the point where the outcomes of the strategies meet. For low 270 $R_0$ , we see convex curves for each of the considered strategies due to the infection curves 271being dominated by the decay of initially infected people, rather than new infections. As  $R_0$ 272273increases, we recover the shape of a standard final size curve as our epidemic takes off (in spite of vaccination). Our second point of interest is where the outcomes of the three considered 274strategies meet, where we define  $R_0 = R'_0 \approx 2.5$ . For  $R_0 < R'_0$ , the optimal strategy is to vac-275cinate Group 1 and the poor strategy is to vaccinate Group 2. For  $R_0 > R'_0$  we find that the 276 optimal strategy is to vaccine Group 2 and the poor strategy is to vaccinate Group 1. Hence, as 277we approach  $R_0 = R'_0$ , our optimal and poor strategies approach one another before swapping. 278279

Qualitatively, we see a difference in outcome for all strategies as we vary  $R_0$ . While the difference in outcome for high and low  $R_0$  depends on the strategy we choose, for all strategies total infections are monotonically increasing with  $R_0$ . The importance of choosing the optimal strategy also varies with  $R_0$ , with the largest differences between the optimal and poor



(a) Total infections for a vaccine that reduces susceptibility by 75% with 50% coverage for three allocation strategies as we continuously vary  $R_0$ .



11

(b) Total deaths for a vaccine that reduces the probability of severe disease by 75% with 50% coverage for a range of allocation strategies as we vary the probability of dying due to infection ( $\sigma_i$ ) for each population group.

**Figure 2:** Comparing the differences between strategies for varying vaccine mechanisms and allocation objectives as we vary  $R_0$  and  $\sigma_i$ .

strategies being when  $R_0$  is between 1 and 2. While as  $R_0$  increases above 5, the outcome for all strategies gets consistently worse and the difference between strategies decreases.

Figure 2b shows how differences in outcomes between strategies change as we vary the prob-286ability of dying due to infection for each population group  $(\sigma_{i \in \{1,2\}})$ . We consider three 287scenarios  $\sigma_i$ :  $\sigma_1 > \sigma_2$ ,  $\sigma_1 = \sigma_2$ , and  $\sigma_1 < \sigma_2$ . The biggest difference in outcomes of strategies 288happens when  $\sigma_1 \neq \sigma_2$ . When  $\sigma_1 = \sigma_2$ , the only factor influencing the difference in deaths 289 290between population groups is their relative susceptibility (as defined previously). Hence, while there is a difference in the number of people infected in each population group, vaccination 291292will reduce the probability of dying due to disease to the same value for each group. However, when  $\sigma_1 \neq \sigma_2$ , one group will be more likely to die due to disease. Therefore, vaccinating the 293group more likely to die due to disease will reduce more deaths than vaccinating the other 294 group, widening the gap between the outcomes of various strategies. For parameters with only 295direct effects, such as  $\sigma_i$ , vaccination only affects vaccinated people. The difference between 296outcomes of allocation strategies is therefore dependent on how the parameters for each group 297 298 compare to one another.

299

300 The two examples presented in Figure 2 demonstrate how direct and indirect affects of vac-

### 12

cination impact the differences in outcomes between optimal and suboptimal strategies. For 301 parameters affecting transmission (e.g.  $R_0$ ) the difference between outcomes of strategies is 302 dependent on the value of the parameter itself. This is due to its affect on transmission 303 for both population groups. However, for parameters affecting individual infection (e.g.  $\sigma_i$ ) 304 the difference between outcomes of strategies is dependent on the relative parameter values 305 between each population group. The biggest differences between outcomes of strategies will 306 occur with there is large disparity in the parameter between groups, and the smallest difference 307 when both groups are equal. 308

**3.2.** Varying vaccine characteristics. We now consider an example population to demonstrate how vaccine effectiveness and coverage affect the differences in outcomes between allocation strategies. We define Group 1 to be more susceptible, more likely to develop symptomatic disease and more likely to die due to disease, and Group 2 to be less susceptible, less likely to develop symptomatic disease and less likely to die due to disease.

314


Figure 3 compares the differences between allocation strategies for various vaccine mechanisms and allocation objectives as we vary vaccine effectiveness and coverage.

317


Figures 3a and 3b show the total infections for vaccines that affect transmission as vaccine 318 effectiveness and coverage are varied. For the considered parameters, the optimal strategy 319 changes from prioritising vaccination for Group 2 to prioritising vaccination for Group 1 at 320 63% effectiveness (3a). For both vaccine effectiveness and coverage, as we saw in Figure 2a, as 321 we increase our vaccine parameter we reduce our objective for all allocation strategies. As the 322 vaccine tends towards becoming 100% effective, or there is high coverage (80%), the optimal 323 strategy produces a much better result than other strategies. However, for lower effectiveness 324 and coverage, increasing the either parameter decreases our objective for all strategies. This 325demonstrates that, in our model, securing better vaccines or more vaccines will work to de-326 crease our objective, even under a suboptimal strategy. 327

328


Figures 3c and 3d show how total symptomatic infections and total deaths for vaccines that affect individual infection vary and we change vaccine effectiveness and coverage. In Figure 3d the difference between optimal and suboptimal strategies is much smaller for 20% and 80% coverage than 50% as there are fewer ways to allocate vaccines for 20% and 80% coverage than for 50% coverage. As vaccine effectiveness and coverage increase, there is a large reduction in outcome for optimal (and close to optimal) strategies, but a much smaller improvement for poor strategies. As vaccination only impacts infected people, vaccinating the less vul-




(a) Total infections for a vaccine that reduces susceptibility for three allocation strategies as we vary vaccine effectiveness.



(c) Total symptomatic infections for a vaccine that reduces the probability of developing symptomatic infection for three allocation strategies as we vary vaccine effectiveness.



(b) Total infections for a vaccine that reduces infectivity for a range of allocation strategies as we vary vaccine coverage. Note the change in axis scale due to limited effect from a vaccine that reduces infectivity.



(d) Total deaths for a vaccine that reduces the infection fatality rate for a range of allocation strategies as we vary vaccine coverage.

**Figure 3:** Comparing the differences between strategies for varying vaccine mechanisms and allocation objectives as we vary vaccine effectiveness and coverage.

336 nerable, who are already unlikely to experience symptomatic or severe disease, does little

337 to reduce an objective focused on these infection characteristics. Unlike a vaccine affecting

transmission, where increasing quality or quantity of vaccines works to decrease the objective for all strategies, here there is only a sizeable reduction for the best strategies. This indicates

that strategy remains important even when effective vaccines and high coverage is available.

14

For our model, allocating poorly with an effective vaccine or high coverage could result in a much worse outcome than allocating well with an ineffective vaccine or lower vaccine coverage.

For our model and the parameters we chose, the difference between optimal and suboptimal 344 strategies varies as we change vaccine effectiveness and coverage based on both vaccine mech-345 anism and allocation objective. If a vaccine mechanism affects transmission, this will impact 346 the total number of infections, and therefore also the total symptomatic infections and total 347 deaths resulting from these infections. Hence for any of these objectives, increasing vaccine 348 effectiveness or coverage will result in a better outcome for all strategies. However, if a vaccine 349 350 mechanism only results in direct effects, this will only impact objectives associated with the mechanism. For example, a vaccine that reduces the probability of dying due to disease will 351have no impact on total infections or total symptomatic infections. When the vaccine mecha-352 nism does impact an objective, increasing vaccine effectiveness and coverage is only effective 353 when an optimal, or close to optimal, strategy is employed. 354

4. Discussion. Our results demonstrate that the difference between outcomes of vaccine 355 allocation strategies depends on both disease and vaccine characteristics. The difference in 356 outcomes between strategies is dependent on whether a considered parameter directly or in-357 directly impacts the outcome. For the former the difference between strategies is dependent 358 heavily on the parameter value itself, whereas for the latter the difference is dependent on 359 the relative values of the parameter between population groups. Furthermore, a vaccine with 360 direct effects will only impact vaccinated people, and so in our model poor vaccine resources 361 allocated well can result in a better outcome than good vaccine resources allocated poorly. 362 Conversely, if vaccination indirectly effects the outcome, better vaccine resources will result 363 in a better outcome for all strategies. These findings emphasise the importance of identifying 364 365 the direct and indirect effects of vaccination when determining allocation strategy.

366

367 By investigating allocation strategies for individual vaccine mechanisms and objectives, we lay foundations for a model that considers multi-mechanism or multi-objective strategies. 368 When designing vaccine strategies with little knowledge about the specifics of the vaccine, 369 modelling often assumes individual mechanisms, or simply a vaccine that provides protection 370 [7, 15, 16]. When vaccines eventually become available and are observed to include multiple 371 mechanisms, these mechanisms are built into models through using effectiveness parameters 372 373 from data [17, 18, 19]. Our model incorporates multiple possible vaccine mechanisms, however we restrict our analysis to the impact of each separately. 374

15

Furthermore, in this paper we have considered objectives that are not strictly independent 376 of one another. Due to our model assumptions, reducing infections leads to a reduction in 377 symptomatic infections which further leads to a reduction in deaths. However, by consider-378 ing the impacts of vaccination on transmission or individual infection, we can determine the 379 impact of various disease and vaccine characteristics on the outcome of independent objec-380 tives. To consider allocation strategies for multiple objectives would require development of 381 a single objective through weighting individual objectives based on importance. The impact 382 of vaccination on this overarching objective could then be thought of in terms of the impact 383 of vaccination on each individual part, as described in our results. 384

385 While our model is sufficient to start learning about the importance of different vaccine mechanisms, it may not describe specific, realistic scenarios. In our model, we assume SEIR dynamics 386 and divide the population into people with high and low risk to infection. To model a more 387 realistic scenario, we would likely need to extend our model to capture a more complex pop-388 ulation and transmission structure. In particular, we assumed constant vaccine effectiveness 389 across our population, but age dependent vaccine effectiveness has been observed, for example 390 391 for influenza vaccines [20]. When considered in the model, this could alter not only the op-392 timal vaccination strategy, but also the difference between optimal and suboptimal strategies [3, 16, 21]. While the simplicity of our model allows us to analyse the differences in outcomes 393 394 between optimal and suboptimal strategies, more information and a model incorporating observed heterogeneities are needed to produce results for a realistic vaccination scenario. 395 396

By investigating how various factors impact the outcomes of vaccination strategies in our 397 398 model, we explore the idea of prioritising vaccine allocation over ascertainment. When new scenarios arise, such as new vaccines available or new variants appearing, our results allows 399 us to compare how allocation strategies differ in this new scenario compared to an old sce-400 nario. Is it still worth sourcing more vaccines with the current allocation strategy or will 401 increased coverage only improve the outcome if we vaccinate more effectively? How great are 402the benefits from allocating vaccines optimally now that our vaccine is less effective against 403 a new variant? Do suboptimal strategies perform similarly? Our results show that investi-404 405 gating how individual disease and vaccine characteristics impact the difference in outcomes between vaccination strategies allows the reassessment of vaccine allocation as information on 406 an emerging disease becomes available and reinforces the need to carefully consider allocation 407 strategy when distributing vaccines. 408

410	<b>Code availability.</b> The MATLAB code used to generate all results in this manuscript is
411	available online https://github.com/iabell/vaccine_allocation.
412	Supplementary materials. Additional figures and model details can be found in the sup-
413	plementary materials.
414	REFERENCES
415	[1] Australian health management plan for pandemic influenza. Technical report, Australian Government
416	Department of Health, 2019.
417	[2] Brian J Coburn, Bradley G Wagner, and Sally Blower. Modeling influenza epidemics and pandemics
418	insights into the future of swine flu (H1N1). BMC Medicine, 7(1):30, December 2009.
419	[3] Jonathan Dushoff, Joshua B Plotkin, Cecile Viboud, Lone Simonsen, Mark Miller, Mark Loeb, and David
420	J. D Earn. Vaccinating to Protect a Vulnerable Subpopulation. PLoS Medicine, 4(5):e174, May 2007.
421	[4] C. Degeling, J. Williams, S.M. Carter, R. Moss, P. Massey, G.L. Gilbert, P. Shih, A. Braunack-Mayer
422	K. Crooks, D. Brown, and J. McVernon. Priority allocation of pandemic influenza vaccines in Australia
423	- Recommendations of 3 community juries. Vaccine, 39(2):255–262, January 2021.
424	[5] Matthew James Keeling and Pejman Rohani. Modeling infectious diseases in humans and animals. Prince-
425	ton University Press, Princeton, 2008. OCLC: ocn163616681.
426	[6] Matt J. Keeling and Peter J. White. Targeting vaccination against novel infections: risk, age and spatial
427	structure for pandemic influenza in Great Britain. Journal of The Royal Society Interface, 8(58):661-
428	670, May 2011. Publisher: Royal Society.
429	[7] Eunha Shim. Optimal Allocation of the Limited COVID-19 Vaccine Supply in South Korea. Journal o
430	Clinical Medicine, 10(4):591, February 2021.
431	[8] Brody H. Foy, Brian Wahl, Kayur Mehta, Anita Shet, Gautam I. Menon, and Carl Britto. Comparing
432	COVID-19 vaccine allocation strategies in India: A mathematical modelling study. Internationa
433	journal of infectious diseases: IJID: official publication of the International Society for Infectious
434	Diseases, 103:431–438, February 2021.
435	[9] Georgina Kenyon. Australia's struggle with the delta variant. The Lancet Infectious Diseases, 21(10):1358
436	October 2021. Publisher: Elsevier.
437	[10] Elie Dolgin. Omicron is supercharging the COVID vaccine booster debate. Nature, December 2021
438	Bandiera_abtest: a Cg_type: News Publisher: Nature Publishing Group Subject_term: SARS-CoV-2
439	Virology, Immunology, Public health, Vaccines.
440	[11] Sunmi Lee, Michael Golinski, and Gerardo Chowell. Modeling Optimal Age-Specific Vaccination Strate-
441	gies Against Pandemic Influenza. Bulletin of Mathematical Biology, 74(4):958–980, April 2012.
442	[12] William J. M. Probert, Katriona Shea, Christopher J. Fonnesbeck, Michael C. Runge, Tim E. Carpen-
443	ter, Salome Dürr, M. Graeme Garner, Neil Harvey, Mark A. Stevenson, Colleen T. Webb, Marleen
444	Werkman, Michael J. Tildesley, and Matthew J. Ferrari. Decision-making for foot-and-mouth disease
445	control: Objectives matter. <i>Epidemics</i> , 15:10–19, June 2016.
446	[13] Mingmei Teo, Nigel Bean, and Joshua V. Ross. Optimised prophylactic vaccination in metapopulations
447	<i>Epidemics</i> , 34:100420, March 2021.
448	[14] Jan Medlock and Alison P. Galvani. Optimizing Influenza Vaccine Distribution. Science, 325(5948):1705–
449	1708, September 2009. Publisher: American Association for the Advancement of Science.

- [15] Laura Matrajt, Julia Eaton, Tiffany Leung, and Elizabeth R. Brown. Vaccine optimization for COVID-19:
   Who to vaccinate first? *Science Advances*, 7(6):eabf1374, February 2021.
- [16] Sam Moore, Edward M. Hill, Louise Dyson, Michael J. Tildesley, and Matt J. Keeling. Modelling optimal
   vaccination strategy for SARS-CoV-2 in the UK. *PLOS Computational Biology*, 17(5):e1008849, May
   2021. Publisher: Public Library of Science.
- [17] Laura Matrajt, Julia Eaton, Tiffany Leung, Dobromir Dimitrov, Joshua T. Schiffer, David A. Swan, and
  Holly Janes. Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of singledose vaccination. *Nature Communications*, 12(1):3449, June 2021. Number: 1 Publisher: Nature
  Publishing Group.
- [18] Nicholas Steyn, Michael J. Plank, Rachelle N. Binny, Shaun C. Hendy, Audrey Lustig, and Kannan
  Ridings. A COVID-19 vaccination model for Aotearoa New Zealand. *Scientific Reports*, 12(1):2720,
  February 2022. Number: 1 Publisher: Nature Publishing Group.
- [19] Jodie McVernon, David J Price, Patricia T. Campbell, Nick Golding, Christopher M. Baker, James
  Walker, Nic Geard, Freya M Shearer, Eamon Conway, Michael Lydeamore, James Wood, Nic Rebuli,
  and Joel Miller. Doherty Institute Modelling Report for National Cabinet. Technical report, Doherty
  Institute, March 2021.
- 466 [20] Katherine Goodwin, Cécile Viboud, and Lone Simonsen. Antibody response to influenza vaccination in
   467 the elderly: A quantitative review. Vaccine, 24(8):1159–1169, February 2006.
- 468 [21] Ashleigh R. Tuite, David N. Fisman, Jeffrey C. Kwong, and Amy L. Greer. Optimal Pandemic Influenza
   469 Vaccine Allocation Strategies for the Canadian Population. *PLoS ONE*, 5(5):e10520, May 2010.